Opaleye Management
Latest statistics and disclosures from Opaleye Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are HROW, TGTX, OCUL, ARVN, CDXS, and represent 55.77% of Opaleye Management's stock portfolio.
- Added to shares of these 10 stocks: ARVN (+$17M), CDXS (+$16M), LQDA (+$14M), Ginkgo Bioworks Holdings Inc Cl A (+$6.7M), ZNTL, ETON, RZLT, IMNM, KROS, ABCL.
- Started 6 new stock positions in PEPG, Ginkgo Bioworks Holdings Inc Cl A, RVNC, RZLT, ZNTL, Adagio Med Hldgs.
- Reduced shares in these 10 stocks: CPRX (-$11M), FDMT (-$7.3M), IOVA (-$7.2M), CYTK (-$6.5M), NTLA, LXRX, APLT, SVRA, VTYX, VSTM.
- Sold out of its positions in ALGS, DSGN, FDMT, FULC, NTLA, IOVA, KPTI, LXRX, PMVP, RPHM. SVRA, VTYX, VSTM.
- Opaleye Management was a net buyer of stock by $6.0M.
- Opaleye Management has $600M in assets under management (AUM), dropping by 36.99%.
- Central Index Key (CIK): 0001595855
Tip: Access up to 7 years of quarterly data
Positions held by Opaleye Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Opaleye Management
Opaleye Management holds 44 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Harrow Health (HROW) | 29.9 | $179M | 4.0M | 44.96 |
|
|
| Tg Therapeutics (TGTX) | 8.9 | $53M | 2.3M | 23.39 |
|
|
| Ocular Therapeutix (OCUL) | 7.3 | $44M | -5% | 5.0M | 8.70 |
|
| Arvinas Ord (ARVN) | 5.2 | $31M | +126% | 1.3M | 24.63 |
|
| Codexis (CDXS) | 4.5 | $27M | +153% | 8.8M | 3.08 |
|
| Rhythm Pharmaceuticals (RYTM) | 4.4 | $26M | -2% | 500k | 52.39 |
|
| Keros Therapeutics (KROS) | 3.8 | $23M | +7% | 395k | 58.07 |
|
| Immunome (IMNM) | 3.0 | $18M | +12% | 1.2M | 14.62 |
|
| Liquidia Corporation Com New (LQDA) | 2.8 | $17M | +422% | 1.7M | 10.00 |
|
| Eton Pharmaceuticals (ETON) | 2.8 | $17M | +16% | 2.8M | 6.00 |
|
| Edgewise Therapeutics (EWTX) | 2.3 | $14M | -9% | 523k | 26.69 |
|
| Cargo Therapeutics (CRGX) | 2.0 | $12M | -2% | 541k | 21.86 |
|
| Applied Therapeutics (APLT) | 1.9 | $11M | -21% | 1.3M | 8.50 |
|
| Vaxcyte (PCVX) | 1.6 | $9.7M | 85k | 114.27 |
|
|
| Nurix Therapeutics (NRIX) | 1.6 | $9.4M | 420k | 22.47 |
|
|
| Acelyrin (SLRN) | 1.6 | $9.3M | +19% | 1.9M | 4.93 |
|
| Trevi Therapeutics (TRVI) | 1.4 | $8.6M | -2% | 2.6M | 3.34 |
|
| Biodesix (BDSX) | 1.2 | $7.0M | -5% | 3.8M | 1.83 |
|
| Ginkgo Bioworks Holdings Class A New | 1.1 | $6.7M | NEW | 820k | 8.15 |
|
| Jasper Therapeutics Com New (JSPR) | 1.1 | $6.6M | -9% | 354k | 18.81 |
|
| Xoma Corp Del Com New (XOMA) | 1.1 | $6.6M | 250k | 26.48 |
|
|
| Nuvalent Inc-a (NUVL) | 1.1 | $6.5M | +7% | 64k | 102.30 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.9 | $5.6M | +6% | 335k | 16.60 |
|
| Urogen Pharma (URGN) | 0.9 | $5.1M | 404k | 12.70 |
|
|
| Protagonist Therapeutics (PTGX) | 0.8 | $4.7M | 105k | 45.00 |
|
|
| Gossamer Bio Note 5.000% 6/0 (Principal) | 0.7 | $4.2M | 8.0M | 0.52 |
|
|
| Cytokinetics Com New (CYTK) | 0.7 | $4.0M | -62% | 75k | 52.80 |
|
| Karyopharm Therapeutics Note 3.000%10/1 (Principal) | 0.7 | $4.0M | 6.0M | 0.66 |
|
|
| Gossamer Bio (GOSS) | 0.6 | $3.7M | -6% | 3.7M | 1.01 |
|
| Zentalis Pharmaceuticals (ZNTL) | 0.6 | $3.6M | NEW | 967k | 3.68 |
|
| Protara Therapeutics Com Stk (TARA) | 0.5 | $3.1M | -27% | 1.7M | 1.83 |
|
| Rezolute Com New (RZLT) | 0.4 | $2.3M | NEW | 467k | 4.85 |
|
| Catalyst Pharmaceutical Partners (CPRX) | 0.4 | $2.2M | -82% | 113k | 19.88 |
|
| Abcellera Biologics (ABCL) | 0.3 | $2.1M | +300% | 800k | 2.60 |
|
| Lyell Immunopharma (LYEL) | 0.3 | $1.9M | -16% | 1.4M | 1.38 |
|
| Allakos (ALLK) | 0.3 | $1.6M | -13% | 2.4M | 0.65 |
|
| Relmada Therapeutics (RLMD) | 0.3 | $1.6M | -20% | 480k | 3.24 |
|
| Pepgen (PEPG) | 0.3 | $1.5M | NEW | 179k | 8.55 |
|
| Revance Therapeutics (RVNC) | 0.2 | $1.4M | NEW | 275k | 5.19 |
|
| Syros Pharmaceuticals Com New (SYRS) | 0.2 | $1.4M | -24% | 655k | 2.15 |
|
| Aerovate Therapeutics (AVTE) | 0.2 | $920k | 440k | 2.09 |
|
|
| Regulus Therapeutics (RGLS) | 0.1 | $840k | -63% | 535k | 1.57 |
|
| Ibio Com New (IBIO) | 0.1 | $833k | 375k | 2.22 |
|
|
| Adagio Med Hldgs | 0.0 | $285k | NEW | 111k | 2.58 |
|
Past Filings by Opaleye Management
SEC 13F filings are viewable for Opaleye Management going back to 2013
- Opaleye Management 2024 Q3 filed Nov. 14, 2024
- Opaleye Management 2024 Q2 filed Aug. 14, 2024
- Opaleye Management 2024 Q1 restated filed May 29, 2024
- Opaleye Management 2024 Q1 filed May 15, 2024
- Opaleye Management 2023 Q4 filed Feb. 14, 2024
- Opaleye Management 2023 Q3 filed Nov. 15, 2023
- Opaleye Management 2023 Q2 filed Aug. 14, 2023
- Opaleye Management 2023 Q1 filed May 15, 2023
- Opaleye Management 2022 Q4 filed Feb. 10, 2023
- Opaleye Management 2022 Q3 filed Nov. 14, 2022
- Opaleye Management 2022 Q2 filed Aug. 15, 2022
- Opaleye Management 2022 Q1 filed May 16, 2022
- Opaleye Management 2021 Q4 filed Feb. 14, 2022
- Opaleye Management 2021 Q3 filed Nov. 16, 2021
- Opaleye Management 2021 Q2 filed Aug. 16, 2021
- Opaleye Management 2021 Q1 filed May 18, 2021